Clinical Trial Update: A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SY-3505 to crizotinib in first-line ALK-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)
• SY-3505

Snippet

Sponsor: Shouyao Holdings (Beijing) Co. LTD | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING